BIIB - Pharmas engaged in Alzheimer's the 'holy grail' of drug development

Finding a treatment that can actually slow the progression of Alzheimer's disease has been referred to as the "holy grail" of drug development.The highway of Alzheimer's drug development is littered with failed candidates that have largely targeted the buildup of beta amyloid, a protein in the brain that is found in many patients with the disease.However, recent developments from several companies is providing newfound hope.Anavex Life Sciences' (AVXL) lead asset, Anavex2-73, is currently undergoing a phase 2b/3 study in Alzheimer's.Earlier this month, Cassava Sciences (SAVA) released positive interim data from an open-label study of its lead Alzheimer's candidate, simufilam.In its latest quarterly filing, Cyclo Therapuetics (CYTH) disclosed it struck an agreement with a CRO for a clinical trial to evaluate the safety and efficacy of Trappsol Cyclo for Alzheimer’s.AC Immune (NASDAQ:ACIU) said that its anti-pTau vaccine candidate against Alzheimer's, under development with Johnson & Johnson's (JNJ) Janssen unit, generated positive interim results from an ongoing

For further details see:

Pharmas engaged in Alzheimer's, the 'holy grail' of drug development